SHPH on Nasdaq

Shuttle Pharmaceuticals Holdings, Inc.

American pharmaceutical preparations company based in Gaithersburg. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerSHPH on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersGaithersburg, Maryland1
  • Incorporated inDE2
  • Business address401 Professional Drive, Suite 260, Gaithersburg, Md 208792
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income3456-$11.9M in 2025+584% since 2021
-$15.0M-$10.0M-$5.0M02021: -$1.7M-$1.7M20212022: -$2.3M-$2.3M2022+34%2023: -$5.9M-$5.9M2023+151%2024: -$7.7M-$7.7M2024+31%2025: -$11.9M-$11.9M2025+55%
Net income3456-$11.7M in 2025+917% since 2021
-$15.0M-$10.0M-$5.0M02021: -$1.2M-$1.2M20212022: -$5.0M-$5.0M2022+334%2023: -$6.6M-$6.6M2023+32%2024: -$9.1M-$9.1M2024+39%2025: -$11.7M-$11.7M2025+28%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Research and development$4.1M$3.6M
General and administrative$5.7M$1.4M
Legal and professional$2.2M$2.7M
Total operating expenses$11.9M$7.7M
Net loss from operations-$11.9M-$7.7M
Interest income$1.1K$38.1K
Convertible notes finance fee-$152.7K
Change in fair value of derivative liabilities-$74.4K$555.8K
Change in fair value of convertible notes-$3.4K$122.6K
Gain on sale of marketable securities$28.6K
Gain on settlement of debt$342.6K
Loss on settlement of convertible debt-$833.5K
Total other (expense) income$195.2K-$1.4M
Net loss-$11.7M-$9.1M
Weighted average common shares outstanding - basic1.6M shares114.8K shares
Net loss per shares - basic-$7.16-$79.65
Weighted average common shares outstanding - diluted1.6M shares115.5K shares
Net loss per share - diluted-$7.16-$82.60

Compare Shuttle Pharmaceuticals Holdings, Inc. with another company

Leadership

Who has led Shuttle Pharmaceuticals Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Anatoly Dritschilo2022–2023
  2. Chris Cooper2025–2026
  3. Ryan Trasolini2026–now

Chair

  1. Anatoly Dritschilo2022–2023

President

  1. Peter Dritschilo2022

Chief financial officer

  1. Hoek Michael Vander2022–2024
  2. Timothy J. Lorber2024–2026
  3. Yuying Liang2026–now

Chief operating officer

  1. Peter Dritschilo2022
2025
Board members and other officers (14)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Vice President - Operations and RegulatoryMichael Vander Hoek named Jan 4, 2022 to Oct 25, 202430
  • President and Chief Operating OfficerPeter Dritschillo named Feb 22, 2022 to Aug 15, 202231
  • DirectorSachin Pathigoda named Nov 7, 202532
  • DirectorGeorge Scorcis named Jun 26, 202533

Timeline

  1. Jun 1, 2026New chief executive Ryan Trasolini becomes CEO9
  2. Apr 2, 2025New chief executive Chris Cooper becomes CEO10
  3. Sep 7, 2022New chief executive Anatoly Dritschilo becomes CEO11

Filings

304 filings to the SEC since October 2021: 5 annual reports, 13 quarterly reports, 101 major events, 56 insider forms, 6 large holders, 8 private raises, 115 other. The latest 20:

  1. Sep 24, 202610-Q EDGAR
  2. Sep 24, 20268-K/A EDGAR
  3. Sep 16, 20268-K EDGAR
  4. Sep 11, 20268-K EDGAR
  5. Sep 2, 2026DEFA14A EDGAR
  6. Sep 2, 20268-K EDGAR
  7. Sep 1, 20268-K EDGAR
  8. Aug 28, 20268-K EDGAR
  9. Aug 17, 2026NT 10-Q EDGAR
  10. Aug 17, 20268-K/A EDGAR
  11. Aug 13, 2026DEFA14A EDGAR
  12. Aug 13, 2026DEF 14A EDGAR
  13. Aug 3, 2026PRE 14A EDGAR
  14. Jul 15, 20264 PRIMARY DOCUMENT EDGAR
  15. Jul 13, 20264 PRIMARY DOCUMENT EDGAR
  16. Jul 13, 20263 PRIMARY DOCUMENT EDGAR
  17. Jul 9, 20264 PRIMARY DOCUMENT EDGAR
  18. Jul 7, 20264 PRIMARY DOCUMENT EDGAR
  19. Jul 2, 20264 PRIMARY DOCUMENT EDGAR
  20. Jul 1, 20268-K EDGAR

The 304 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 6 buys and 17 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 14, 2026HRT FINANCIAL LP10% ownerSale82,116$4.48$367.9KForm 4
Jul 13, 2026HRT FINANCIAL LP10% ownerSale1,033$4.67$4.8KForm 4
Jul 10, 2026HRT FINANCIAL LP10% ownerBuy731$3.11$2.3KForm 4
Jul 9, 2026HRT FINANCIAL LP10% ownerBuy8,266$3.38$27.9KForm 4
Jul 8, 2026HRT FINANCIAL LP10% ownerSale18,531$3.52$65.2KForm 4
Jul 7, 2026HRT FINANCIAL LP10% ownerSale10,580$3.33$35.2KForm 4
Jul 6, 2026HRT FINANCIAL LP10% ownerSale9,022$3.51$31.7KForm 4
Jul 2, 2026HRT FINANCIAL LP10% ownerBuy7,851$3.54$27.8KForm 4
Jul 1, 2026HRT FINANCIAL LP10% ownerBuy3,959$3.30$13.1KForm 4
Jun 30, 2026HRT FINANCIAL LP10% ownerBuy6,755$3.23$21.8KForm 4
Jun 29, 2026HRT FINANCIAL LP10% ownerBuy25,836$3.44$88.9KForm 4
Dec 13, 2023Brown MiltonDirectorSale2,921$0.46$1.3KForm 4
Dec 13, 2023Jacobs BetteDirectorSale4,157$0.46$1.9KForm 4
Dec 29, 2022Senanayake ChrisDirectorSale1,626$1.61$2.6KForm 4
Dec 29, 2022Richards Steven MDirectorSale995$1.61$1.6KForm 4
Dec 29, 2022Adkins WilliamSale995$1.61$1.6KForm 4
Dec 29, 2022Brown MiltonDirectorSale995$1.61$1.6KForm 4
Dec 29, 2022Dritschilo AnatolyCEO and ChairmanSale8,372$1.61$13.5KForm 4
Dec 29, 2022Rich TyvinChief Medical OfficerSale1,414$1.61$2.3KForm 4
Dec 29, 2022Jung MiraChief Scientific OfficerSale328$1.61$528Form 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 30, 2026Raised $10 million in a private offering of equity Form D: 47 investors so far Form D
  2. Nov 3, 2025Raised $2.5 million in a private offering of securities Form D: $2.5 million offered in all Form D
  3. Jun 20, 2025Raised $4.2 million in a private offering of equity Form D: 1 investor so far Form D
  4. Oct 14, 2024Raised $790,000 in a private offering of securities Form D: $1.3 million offered in all Form D
  5. Jan 11, 2023Raised $4 million in a private offering of securities Form D: 1 investor so far Form D
  6. Aug 1, 2022Raised $125,000 in a private offering of debt Form D: $500,000 offered in all Form D
  7. Feb 8, 2022Raised $365,000 in a private offering of debt Form D: $2 million offered in all Form D
  8. Dec 28, 2021Raised $500,000 in a private offering of debt Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC24,354$79.2K0.0%New
Barclays PLC750$2.4K0.0%New
Tower Research Capital LLC (TRC)389$1.3K0.0%New
Kelleher Financial Advisors120$3900.0%New
Hrt Financial LP78,597$2550.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35